semaglutide manufacturers in india pharma companies develop versions of Wegovy to get on weight-loss windfall Why Semaglutide is an inflection

Additionally, most mechanistic studies rely on animal models, raising concerns about translatability to humans due to interspecies differences in GLP-1R distribution and signaling ( The latest diabetic retinopathy preferred practice guidelines from the American Academy of Ophthalmology indicate that the rising use of GLP-1RAs may lead to quick glycemic control and severe hypoglycemia and has been reported to cause higher rates of retinopathy complications, especially in patients with early-stage DR (Lim et al., 2025)

Medicare is statutorily prohibited from covering obesity medications, and Congressional efforts to change that rule have been unsuccessful

doi: 10.1186/s12933-024-02436-3, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 21

Loureno et al

The body appears to recalibrate its cardiovascular response over time, potentially through downregulation of glucagon receptor sensitivity in cardiac tissue or compensatory autonomic adjustments

YesMedicare Can Now Cover Wegovy (Two Pathways) As of July 1, 2026, Medicare can cover Wegovy for weight loss through the new Medicare GLP-1 Bridge a flat $50/month , covering all Wegovy formulations (injection and oral tablets)